Infliximab and Antibodies to Infliximab Quantitation
Ordering Recommendation
Use to monitor infliximab or infliximab biosimilar therapy.
New York DOH Approval Status
Specimen Required
Collect specimen before next scheduled dose of infliximab or infliximab biosimilar (trough specimen). Avoid exposure to biotin (vitamin B7) for 12 hours prior to specimen collection.
Serum separator tube.
Separate serum from cells ASAP. Transfer 1 mL serum to an ARUP standard transport tube. (Min 0.1 mL)
Refrigerated.
Grossly hemolyzed, icteric, or lipemic specimens.
After separation from cells: Ambient: 2 days; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles).
Methodology
Quantitative Electrochemiluminescence Immunoassay (ECLIA) with Acid Dissociation
Performed
Sun-Sat
Reported
3-7 days
Reference Interval
Test Number |
Components |
Reference Interval |
---|---|---|
Infliximab Quantitation | 0.5 ug/mL or greater | |
Antibodies to Infliximab Quantitation | 19 ng/mL or less |
Interpretive Data
Infliximab Quantitation:
Limit of Quantitation = 0.5 ug/mL.
Results of 0.5 ug/mL or higher indicate the detection of infliximab or infliximab biosimilar. Therapeutic level may vary depending on the disease being treated.
Antibodies to Infliximab Quantitation:
Limit of Quantitation = 20 ng/mL.
Results of 20 ng/mL or higher indicate the detection of antibodies against infliximab or an infliximab biosimilar. Interpret in the context of infliximab or infliximab biosimilar trough concentration to determine clinical significance and impact on treatment efficacy.
Laboratory Developed Test (LDT)
Note
Hotline History
Hotline History
CPT Codes
80230; 82397
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
3016780 | Infliximab Quantitation | 86896-8 |
3016781 | Antibodies to Infliximab Quantitation | 86897-6 |
Aliases
- Avsola
- Inflectra
- Ixifi
- Remicade
- Renflexis